Clinical Trial Update: Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL® [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the safety and immunogenicity of a fifth DAPTACEL dose in children 4 to 6 years old who previously completed four doses of Pen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• DAPTACEL (Diphtheria Tetanus Acellular Pertussis Vaccine Adsorbed)
• Pentacel (DTaP-Hib-IPV vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2009-09-28